

Resource Summary Report

Generated by ASWG on Aug 10, 2026

CD56 Antibody, anti-human, PE, REAfinity™

RRID:AB_2726090

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-312, RRID:AB_2726090

Antibody Information

URL: http://antibodyregistry.org/AB_2726090

Proper Citation: Miltenyi Biotec Cat# 130-113-312, RRID:AB_2726090

Target Antigen: CD56

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-100-653. (RRID:AB_2658732).

Antibody Name: CD56 Antibody, anti-human, PE, REAfinity™

Description: This monoclonal targets CD56

Target Organism: human

Clone ID: clone REA196

Antibody ID: AB_2726090

Vendor: Miltenyi Biotec

Catalog Number: 130-113-312

Record Creation Time: 20250820T000302+0000

Record Last Update: 20250820T071313+0000

Ratings and Alerts

No rating or validation information has been found for CD56 Antibody, anti-human, PE, REAfinity™.

No alerts have been found for CD56 Antibody, anti-human, PE, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Ghasabeh AS, et al. (2026) Allogeneic CD56 + cell infusion as a bridge to hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a phase I clinical trial. Cancer immunology, immunotherapy : CII, 75(4).

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. Cell reports. Medicine, 5(11), 101823.

Pettinella F, et al. (2024) Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors. Cell reports. Medicine, 5(2), 101380.

Westhaver LP, et al. (2022) Mitochondrial damage-associated molecular patterns trigger arginase-dependent lymphocyte immunoregulation. Cell reports, 39(8), 110847.

Galbraith MD, et al. (2021) Seroconversion stages COVID19 into distinct pathophysiological states. eLife, 10.

Sullivan KD, et al. (2021) The COVIDome Explorer researcher portal. Cell reports, 36(7), 109527.